Clinical trial
Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients…
NCT02913261 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT02913261 |
|---|---|
| Title | Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation |
| Official title | A Phase III Randomized Open-label Multi-center Study of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation |
| Acronym | REACH2 |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Corticosteroid Refractory Acute Graft vs Host Disease |
| Intervention type | Drug |
| Interventions | Ruxolitinib (RUX), Best Available Therapy (BAT) |
| Enrollment | 310 |
| Start date | Mar 10, 2017 |
| Primary completion | Jun 24, 2019 |
| Completion | Apr 23, 2021 |
| First posted | Sep 23, 2016 |
| Last update posted | Feb 8, 2023 |
| Countries | Australia, Austria, Bulgaria, Canada, Czechia, Denmark, France, Germany, Greece, Hong Kong, Israel, Italy and 10 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: